Devices/Safety Alert·FDA MedWatch Safety Alerts

Anesthesia Kit Correction: Becton Dickinson Issues Correction for BD Spinal Trays Containing Bupivacaine Ampules

MediumPublished Jun 3, 2026· AI-analyzed Jun 3, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Becton Dickinson (BD) issued a correction for specific Spinal Trays involving the removal of Bupivacaine ampule components from the affected kits.

Who it affects

Healthcare facilities using BD Spinal Trays, surgical staff, and departments responsible for anesthesia kit procurement and safety management.

Why it matters

The removal of a primary drug component from a specialized medical device tray suggests a potential quality or safety issue specifically associated with the Bupivacaine ampules within those kits. Regulatory and clinical teams may need to evaluate the impact on surgical workflows and ensure that subsequent anesthetic sourcing maintains the required standards for spinal procedures. The source does not specify the underlying cause (e.g., potency, contamination, or packaging integrity) of the correction.

Practical takeaway

QA and supply chain teams should immediately identify and sequester affected BD Spinal Trays in inventory. Clinical staff must be notified regarding the removal of the Bupivacaine ampule component to ensure alternative anesthetic supplies are available during procedures.

FDA source material

BD is correcting affected Spinal Trays by removing Bupivacaine ampule components

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.